Department of Obstetrics and Gynecology, The First Affiliated Hospital of Bengbu Medical College, Anhui Province, PR China.
Department of Obstetrics and Gynecology, The First Affiliated Hospital of Bengbu Medical College, Anhui Province, PR China.
Clinics (Sao Paulo). 2024 Aug 3;79:100469. doi: 10.1016/j.clinsp.2024.100469. eCollection 2024.
To investigate the relationship between the changes of C-reactive protein to Albumin Ratio (CAR) levels and Interval Debulking Surgery (IDS) outcome after Neoadjuvant Chemotherapy (NAC) in ovarian cancer patients.
A nested case-control study for 209 patients with ovarian cancer who received NAC-IDS therapy from the First Affiliated Hospital of Bengbu Medical College between 2015‒2021 was conducted. Demographic data, laboratory indicators, and imaging examinations were collected. The outcome was regarded as optimal IDS in this study. Univariate and multivariate logistic regression analyses were performed to assess the relationship of CAR before NAC, CAR after NAC and ∆CAR with optimal IDS. The authors also performed the subgroup analysis based on menopausal state.
The end time of follow-up was January 24, 2022. A total of 156 patients had been treated with optimal IDS, and 53 with suboptimal IDS. After adjusting age, body mass index, menopausal state, NAC drug, peritoneal perfusion and CAR before NAC, the result showed that CAR after NAC (Odds Ratio [OR = 3.48], 95% Confidence Interval [95% CI 1.28‒9.48], p = 0.015) and ∆CAR (OR = 0.29, 95% CI 0.11‒0.78, p = 0.015) were associated with optimal IDS, respectively. Additionally, the authors found a significant correlation between CAR after NAC and optimal IDS (OR = 3.16, 95% CI 1.07‒9.35, p = 0.038), and ∆CAR and optimal IDS (OR = 0.32, 95% CI 0.11‒0.94, p = 0.038) among ovarian cancer patients with menopause.
CAR after NAC and ∆CAR were independent prognostic markers of optimal interval debulking surgery for ovarian cancer patients.
探讨新辅助化疗(NAC)后 C 反应蛋白与白蛋白比值(CAR)水平变化与卵巢癌患者间隔肿瘤细胞减灭术(IDS)结局的关系。
对 2015 年至 2021 年蚌埠医学院第一附属医院接受 NAC-IDS 治疗的 209 例卵巢癌患者进行了巢式病例对照研究。收集了人口统计学数据、实验室指标和影像学检查。本研究中,将 IDS 结果视为最佳。采用单因素和多因素逻辑回归分析评估 NAC 前 CAR、NAC 后 CAR 和 ∆CAR 与最佳 IDS 的关系。作者还根据绝经状态进行了亚组分析。
随访截止日期为 2022 年 1 月 24 日。共 156 例患者接受了最佳 IDS 治疗,53 例患者接受了非最佳 IDS 治疗。调整年龄、体重指数、绝经状态、NAC 药物、腹腔灌注和 NAC 前 CAR 后,结果表明,NAC 后 CAR(优势比 [OR] = 3.48,95%置信区间 [95%CI] 1.28-9.48,p = 0.015)和 ∆CAR(OR = 0.29,95%CI 0.11-0.78,p = 0.015)与最佳 IDS 相关。此外,作者发现 NAC 后 CAR 与最佳 IDS 之间存在显著相关性(OR = 3.16,95%CI 1.07-9.35,p = 0.038),而 NAC 后 ∆CAR 与最佳 IDS 之间存在显著相关性(OR = 0.32,95%CI 0.11-0.94,p = 0.038)。
NAC 后 CAR 和 ∆CAR 是卵巢癌患者间隔肿瘤细胞减灭术最佳预后的独立预测标志物。